Compare ProShares UltraPro QQQ ETF (TQQQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs 10X Genomics Inc — how do they compare? ProShares UltraPro QQQ ETF trades at $71.46, while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| TQQQ | TXG | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $67.29 |
52-Week Low | $37.89 | $11.34 |
Market Cap | — | $8.55B |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.16, down 0.29% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights its amplified returns during the AI boom but warns of structural costs like volatility decay. The ETF's performance is closely tied to large-cap tech earnings and market sentiment.
The outlook for TQQQ hinges on continued tech sector strength, particularly AI-driven growth, but risks include high volatility and decay from daily rebalancing. Investors face amplified gains or losses, making it suitable only for those comfortable with significant risk. Monitoring underlying index performance and tech earnings is critical for timing entries and exits.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
